{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:00:18Z","timestamp":1790715618828,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:00:00Z","timestamp":1626307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jcv.2021.104912","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T03:08:49Z","timestamp":1626404929000},"page":"104912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2890-7515","authenticated-orcid":false,"given":"Katharina","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Girl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Giebl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"von Buttlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Dobler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0556-3211","authenticated-orcid":false,"given":"Joachim J.","family":"Bugert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8539-726X","authenticated-orcid":false,"given":"Stefanie","family":"Gruetzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8756-7821","authenticated-orcid":false,"given":"Roman","family":"W\u00f6lfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2021.104912_bib0001","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.26.1.2002106","article-title":"Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020","volume":"26","author":"Leung","year":"2021","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.jcv.2021.104912_bib0002","doi-asserted-by":"crossref","first-page":"e61312","DOI":"10.7554\/eLife.61312","article-title":"Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants","volume":"9","author":"Weisblum","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.jcv.2021.104912_bib0003","article-title":"The impact of Spike mutations on SARS-CoV-2 neutralization","author":"Rees-Spear","year":"2021","journal-title":"Immunology"},{"key":"10.1016\/j.jcv.2021.104912_bib0004","first-page":"1","article-title":"Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies","author":"Hu","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jcv.2021.104912_bib0005","unstructured":"Paul-Ehrlich-Institut News - Recommendation of the Paul-Ehrlich-Institut for the Collection and Manufacture of COVID-19 Convalescent Plasma. https:\/\/www.pei.de\/EN\/newsroom\/hp-news\/2020\/200407-recommendation-pei-covid-19-convalescent-plasma.html;jsessionid=75FE2CC97FB1AC74E8529A023B965614.intranet241. Accessed 15 Mar 2021."},{"key":"10.1016\/j.jcv.2021.104912_bib0006","doi-asserted-by":"crossref","DOI":"10.1515\/cclm-2020-1183","article-title":"Results of the first pilot external quality assessment (EQA) scheme for anti-SARS-CoV2-antibody testing","author":"Haselmann","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jcv.2021.104912_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.jviromet.2021.114122","article-title":"Comparison of two commercial surrogate ELISAs to detect a neutralising antibody response to SARS-CoV-2","volume":"292","author":"M\u00fcller","year":"2021","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jcv.2021.104912_bib0008","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of Protection Induced by Vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.jcv.2021.104912_bib0009","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.abd0831","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jcv.2021.104912_bib0010","doi-asserted-by":"crossref","unstructured":"Planas D., Bruel T., Grzelak L., Guivel-Benhassine F., Staropoli I., Porrot F., Planchais C., Buchrieser J., Rajah M.M., Bishop E., Albert M., Donati F., Behillil S., Enouf V., Maquart M., Gonzalez M., S\u00e8ze J.D., P\u00e9r\u00e9 H., Veyer D., S\u00e8ve A., Simon-Lori\u00e8re E., Fafi-Kremer S., Stefic K., Mouquet H., Hocqueloux L., Werf S van der, Prazuck T., Schwartz O. (2021) Sensitivity of infectious SARS-CoV-2 B1.1.7 and B.1.351 variants to neutralizing antibodies. bioRxiv 2021.02.12.430472. https:\/\/doi.org\/10.1101\/2021.02.12.430472.","DOI":"10.1101\/2021.02.12.430472"},{"key":"10.1016\/j.jcv.2021.104912_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.02.033","article-title":"Reduced neutralization of SARS-CoV-2 B1.1.7 variant by convalescent and vaccine sera","author":"Supasa","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jcv.2021.104912_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2021.03.002","article-title":"SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines","author":"Shen","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jcv.2021.104912_bib0013","doi-asserted-by":"crossref","unstructured":"Skelly D.T., Harding A.C., Gilbert-Jaramillo J., Knight M.L., Longet S., Brown A., Adele S., Adland E., Brown H., Tipton T., Stafford L., Johnson S.A., Amini A., Tan T.K., Schimanski L., Huang K.-.Y.A., Rijal P., Frater J., Goulder P., Conlon C.P., Jeffery K., Dold C., Pollard A.J., Townsend A.R., Klenerman P., Dunachie S.J., Barnes E., Carroll M.W., James W.S. (2021) Vaccine-induced immunity provides more robust heterotypic immunity than natural infection to emerging SARS-CoV-2 variants of concern. https:\/\/www.researchsquare.com. Accessed 18 Mar 2021.","DOI":"10.21203\/rs.3.rs-226857\/v1"},{"key":"10.1016\/j.jcv.2021.104912_bib0014","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","article-title":"Viral targets for vaccines against COVID-19","volume":"21","author":"Dai","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jcv.2021.104912_bib0015","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"PNAS"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653221001797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653221001797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T03:14:27Z","timestamp":1761362067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653221001797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":15,"alternative-id":["S1386653221001797"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2021.104912","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2021.104912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104912"}}